Lyer S, Wang ZG, Akhtari M, Zhao W, Seth P: TargetingTGFbeta signaling for cancer therapy. Cancer Biol Ther 2005, 4:261–266.CrossRef 9. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E: TGFbeta1 and Ha-Ras collaborate in modulating the phenotypic INCB028050 solubility dmso plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996, 10:2462–2477.PubMedCrossRef 10. Kinnman N, Andersson U, Hultcrantz C: In situ expression of transforming growth factor-beta

1–3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C. Scand J Gastroenterol 2000, 35:1294–1300.PubMedCrossRef 11. Rubtsov YP, Rudensky AY: TGFβ signalling in control of T-cell-mediated self-reactivity. Nature Immunol 2007, 7:443–453.CrossRef 12. Itoh S,

Itoh F, Goumans SN-38 clinical trial MJ,PTD: Signaling of transforming growth MK-4827 mw factor-b family members through Smad proteins. Eur J Biochem 2000, 267:6954–6967.PubMedCrossRef 13. Welm AL: TGFβ primes breast tumor cells for metastasis. Cell 2008, 133:27–28.PubMedCrossRef 14. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS, Suh DJ: Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002, 94:175–180.PubMedCrossRef 15. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S: Laminin-5 With Transforming Growth Factor-β1 Induces Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma. Gastroenterology 2005, 129:1375–1383.PubMedCrossRef

16. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, Mullauer L, Kammerer B, Bursch W, Schulte-Hermann R: Levels of transforming Sitaxentan growth factor β and transforming growth factor β receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 1998, 28:717–726.PubMedCrossRef 17. Jaskiewicz K, Chasen MR: Differential expression of transforming growth factor β, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res 1995, 15:559–562.PubMed 18. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD: Transforming growth factor-β1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 2002, 37:233–238.PubMedCrossRef 19. Kim YJ, Lee HS, Im JP, Min BH, Kim HD, Jeong JB, Yoon JH, Kim CY, Kim MS, Kim JY, et al.: Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 2003, 35:196–202.PubMed 20. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, Xue Q: Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003, 129:43–51.PubMedCrossRef 21.